⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLO News
Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
globenewswire.com
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
globenewswire.com
ALLO
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
globenewswire.com
ALLO
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
globenewswire.com
CLLS
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
globenewswire.com
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
globenewswire.com
ALLO
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
globenewswire.com
ALLO